Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
Treprostinil
treprostinil
- Restricted Remodulin -> Miscellaneous Programs
- Non-formulary Miscellaneous Programs
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Tyvaso DPI | POWDER, INHALATION | 16 mcg, 32 mcg, 48 mcg, 64 mcg | ||||
| Tyvaso | SOLUTION, INHALATION | 1.74 mg/2.9 mL | ||||
| Remodulin | SOLUTION, INJECTABLE | 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, 200 mg/20 mL. | ||||
| Orenitram | TABLET, EXTENDED RELEASE, ORAL | 0.125 mg, 0.25 mg, 1 mg, 2.5 mg |
Last updated: Jul. 22, 2024
Remodulin is formulary restricted to use by pulmonology, medical intensivists, cardiology, rheumatology, and pediatric critical care in specific situations:
1. Patients that require transition to Remodulin from another PAH agent (i.e. Veletri) prior to anticipated discharge (transition expected over 24-48 hours).
2. Patient is admitted on Remodulin infusion pump, requires continuation of therapy and home supply is unavailable. If continuing home infusion and pump refill is necessary as inpatient, the drug should be per the patient's home supply as the first option. A customizable infusion is available to order via the **Pharmacy Only** Powerplan (see Tip Sheet here) and allows for order entry of the infusion additive and diluent amounts which can vary by patient.
Any use outside of the above should be prescribed or approved by a PAH cardiology specialist physician.
Tyvaso and Tyvaso DPI are non-formulary. Tyvaso must be used with a specific, expensive inhalation system.
Inpatients may use own supply of Tyvaso DPI. Defer initiation to outpatient setting.
Reviewed: April 27, 2005 (Remodulin), November 18, 2014 (Orenitram), and 26 Sept 2017 (Tyvaso), November 2022 (Tyvaso DPI)
Updated: June 2020 (Remodulin)